SCHEMBL6731498

SCHEMBL6731498

CCCCc1oc2ccccc2c1C(=O)c1cc(-c2ccccc2)c(O)c(-c2ccccc2)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EYA3 Q99504 4/20 0.73
▸ TTR P02766 3/20 0.72
▸ PTPN1 P18031 2/20 0.67
▸ THRB P10828 4/20 0.60
▸ THRA P10827 3/20 0.60
▸ KDM5A P29375 7/20 0.57
▸ KDM4A O75164 3/20 0.57
▸ ING2 Q9H160 1/20 0.57
▸ CYP2C9 P11712 3/20 0.56
▸ ABCB11 O95342 3/20 0.56
▸ ADRA2A P08913 3/20 0.56
▸ OPRM1 P35372 3/20 0.56
▸ SLC6A3 Q01959 3/20 0.56
▸ CYP2C19 P33261 2/20 0.56
▸ MEN1 O00255 2/20 0.56
▸ LMNA P02545 2/20 0.56
▸ PGR P06401 2/20 0.56
▸ TBXA2R P21731 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ DRD1 P21728 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6735773 0.88 CYP2C19 (0.71) EYA3TTRPTPN1THRBCYP2C9
SCHEMBL6335384 0.85 EYA3 (1.00) EYA3TTRPTPN1THRBTHRA
SCHEMBL11847986 0.85 EYA3 (0.78) EYA3TTRPTPN1THRBTHRA
SCHEMBL25389924 0.84 EYA3 (0.82) EYA3TTRPTPN1THRBTHRA
SCHEMBL1287644 0.84 TTR (1.00) EYA3TTRPTPN1THRBTHRA
SCHEMBL11843232 0.84 EYA3 (0.77) EYA3TTRPTPN1THRBTHRA
SCHEMBL6735613 0.83 EYA3 (0.63) EYA3TTRPTPN1THRBTHRA
SCHEMBL27992957 0.83 EYA3 (0.80) EYA3TTRPTPN1THRBTHRA
SCHEMBL9195719 0.82 EYA3 (0.73) EYA3TTRPTPN1THRBTHRA
SCHEMBL21447553 0.81 EYA3 (0.80) EYA3TTRPTPN1THRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6683107-B2 THERAPY OF METABOLISM DISORDERS WYETH 2004-01-27 — — US disclosed
US-20030073709-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia WYETH 2003-04-17 — — US disclosed
US-6451845-B1 ANTIDIABETIC AGENTS WYETH 2002-09-17 — — US disclosed
US-20020035272-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS CORPORATION 2002-03-21 — — US disclosed
US-6248764-B1 ANTIDIABETIC AGENT; HYPOGLYCEMIC AGENT AMERICAN HOME PRODUCTS CORPORATION 2001-06-19 — — US disclosed
US-6103708-A USEFUL IN TREATING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2000-08-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073709-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, FFAR3 EYA3 3536/4885TTR 416/4885PTPN1 178/4885
US-20020035272-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia INSR, GPR119, FFAR3 EYA3 3483/4885TTR 507/4885PTPN1 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback